Cereno Scientific : to present preclinical data for candidate drug CS585 at EHA2023 Hybrid Congress – the premier medical congress for hematology
Cereno Scientific ,a company developing innovative treatments for common and rare cardiovascular disease, today announced that an abstract on preclinical drug candidate CS585 has been... | May 15, 2023
Source: marketscreener.com